Mediation of opioid analgesia by a truncated 6-transmembrane GPCR
Open Access
- 26 May 2015
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 125 (7) , 2626-2630
Abstract
The generation of potent opioid analgesics that lack the side effects of traditional opioids may be possible by targeting truncated splice variants of the μ-opioid receptor. μ-Opioids act through GPCRs that are generated from the Oprm1 gene, which undergoes extensive alternative splicing. The most abundant set of Oprm1 variants encode classical full-length 7 transmembrane domain (7TM) μ-opioid receptors that mediate the actions of the traditional μ-opioid drugs morphine and methadone. In contrast, 3-iodobenzoyl-6β-naltrexamide (IBNtxA) is a potent analgesic against thermal, inflammatory, and neuropathic pain that acts independently of 7TM μ-opioid receptors but has no activity in mice lacking a set of 6TM truncated μ-opioid receptor splice variants. Unlike traditional opioids, IBNtxA does not depress respiration or result in physical dependence or reward behavior, suggesting it acts through an alternative μ-opioid receptor target. Here we demonstrated that a truncated 6TM splice variant, mMOR-1G, can rescue IBNtxA analgesia in a μ-opioid receptor–deficient mouse that lacks all Oprm1 splice variants, ablating μ-opioid activity in these animals. Intrathecal administration of lentivirus containing the 6TM variant mMOR-1G restored IBNtxA, but not morphine, analgesia in Oprm1-deficient animals. Together, these results confirm that a truncated 6TM GPCR is both necessary and sufficient for IBNtxA analgesia.Keywords
This publication has 19 references indexed in Scilit:
- A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with MorphineThe Journal of Pharmacology and Experimental Therapeutics, 2013
- The roles played by highly truncated splice variants of G protein-coupled receptorsJournal of Molecular Signaling, 2012
- Synthesis and Evaluation of Aryl-Naloxamide Opiate Analgesics Targeting Truncated Exon 11-Associated μ Opioid Receptor (MOR-1) Splice VariantsJournal of Medicinal Chemistry, 2012
- Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effectsProceedings of the National Academy of Sciences, 2011
- Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actionsProceedings of the National Academy of Sciences, 2009
- β-Arrestin-biased ligands at seven-transmembrane receptorsTrends in Pharmacological Sciences, 2007
- μ Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethalityMolecular Brain Research, 1998
- Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor geneNature, 1996
- Antisense mapping the MOR‐1 opioid receptor: evidence for alternative splicing and a novel morphine‐6β‐glucuronide receptorFEBS Letters, 1995
- Intrathecal morphine in mice: A new techniqueEuropean Journal of Pharmacology, 1980